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Abstract
Adjuvant chemotherapy is recommended for metastatic canine mammary gland tumor. 
Erythropoietin receptors (EPOR) was once thought to be only expressed on the surfaces of 
the erythroid progenitor cells. Recently, EPOR have been identified in several neoplastic 
cell lines and solid tumors including human and canine mammary gland tumors. Bovine 
lactoferrin (bLF) has several biological activities, including anti-tumor effect on some human 
and animal tumors. Clinical trials have been carried out in human medicine based on these 
effects. In this in vitro study, doxorubicin, recombinant human erythropoietin (rHuEPO) and 
bLF were used separately and in combination in order to determine the effect of different drugs 
on canine mammary gland tumor.  Recombinant human erythropoietin was found to have a 
non-significant effect on the canine mammary gland tumor cell line. Doxorubicin alone gave 
a more promising result in cytotoxic effect of the cells in a dose-dependent manner. Bovine 
lactoferrin however did not show a clear anti-proliferative pattern on the tumor cells. The drug 
combination treatment did not show better anti-proliferative or cytotoxic effect on the cells 
than doxorubicin alone. The combination of these drugs induced growth arrest at G2/M phase.
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